US Visudyne reverse stuns QLT
This article was originally published in Clinica
Executive Summary
QLT's plans for doubling the US market for its macular degeneration product, Visudyne, have been dashed. The US Centers for Medicare and Medicaid Services (CMS) has reversed an October decision and will no longer pay to use the drug on patients with the occult or less serious form of wet age-related macular degeneration.